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1  | INTRODUC TION
Antineutrophil	 cytoplasmic	 antibody	 (ANCA)‐associated	 vasculi‐




Nomenclature	 of	 Vasculitis	 (the	 2012	 CHCC	 definitions).1 On the 
basis	 of	 small‐vessel	 necrotizing	 vasculitis,	 MPA	 mainly	 provokes	
necrotizing	glomerulonephritis	and	pulmonary	capillaritis	and	GPA	
often causes granuloma formation of the upper and lower respi‐
ratory	 tracts	 and	 occasionally	 necrotizing	 glomerulonephritis.	
Meanwhile,	EGPA	is	characterized	by	three	typical	allergic	compo‐
nents	including	asthma,	peripheral	eosinophilia,	and	eosinophil‐rich	
granuloma of the respiratory tracts.1,2
A	 natural	 history	 of	 AAV	 was	 previously	 reported.	 The	 first‐
year	and	the	second‐year	mortality	 rates	were	82%	and	90%,	and	
the main etiology of mortality was uremia as a result of rapidly 
progressive glomerulonephritis.3	 As	 various	 therapeutic	 regimens	
were	developed	and	widely	used,	 the	first‐year	mortality	 rate	was	






















all‐cause	 mortality	 during	 follow‐up	 in	 immunosuppressive	 drug‐
naïve	patients	with	AAV.
2  | MATERIAL S AND METHODS
2.1 | Patients





October	2000	 to	April	 2018;	 (b)	 the	 fulfillment	of	 the	American	




documented medical records precise enough to assess calculate 
BVAS	 and	 FFS	 (2009)6,8;	 (e)	 the	 presence	 of	 the	 results	 of	 peri‐
nuclear	(P)‐ANCA	and	cytoplasmic	(C)‐ANCA	or	myeloperoxidase	
(MPO)‐ANCA	and	proteinase	3	(PR3)‐ANCA	at	diagnosis12;	 (f)	no	
other medical conditions at diagnosis to confuse the classification 
of	AAV,	which	were	 identified	 by	 the	10th	 revised	 International	
Classification	of	Diseases	(ICD‐10)13;	and	(g)	no	history	of	immu‐
nosuppressive	 drugs	 prior	 to	 or	 at	 diagnosis	 of	 AAV,	which	was	
verified	 by	 the	 Korean	 Drug	 Utilisation	 Review	 (DUR)	 system.	
This	study	was	approved	by	the	Institutional	Review	Board	 (IRB)	
of	Severance	Hospital	(4‐2017‐0673),	and	the	patient's	written	in‐
formed	consent	was	waived	by	 the	approving	 IRB,	 as	 this	was	a	
retrospective study.
2.2 | Data at diagnosis of AAV
We	obtained	age	at	diagnosis	and	gender	in	patients	with	AAV.	We	











the	 last	 visit	 for	 patients	with	 remission	 and/or	 survived	patients,	
and we defined it as the period from diagnosis to death for deceased 
patients.	 Since	 chronic	 kidney	 disease,	 end‐stage	 renal	 disease,	
ischemic	 heart	 disease,	 congestive	 heart	 failure,	 interstitial	 lung	
disease,	and	cerebrovascular	disease	belong	 to	 items	of	BVAS,	we	
also counted the number of patients with diabetes mellitus and hy‐
















chi‐square	 and	Fisher's	 exact	 tests.	 Significant	differences	 in	 con‐
tinuous variables between the two groups were compared using the 
Mann‐Whitney	test.	The	optimal	cutoffs	of	 laboratory	variables	at	
diagnosis	for	severe	AAV	were	extrapolated	by	calculating	the	area	
under	 the	 receiver	operator	characteristic	 curve	 (AUROC)	and	se‐
lecting	the	point	to	maximize	the	sum	of	sensitivity	and	specificity.	
The	odds	ratio	(OR)	was	assessed	using	the	multivariable	logistic	re‐
gression analysis of variables with P	values	<.05	on	the	univariable	
logistic	regression	analysis.	The	relative	risk	(RR)	of	the	optimal	cut‐
off	was	analyzed	using	contingency	tables	and	the	chi‐square	test.	




3.1 | Baseline characteristics of patients with AAV
Demographic,	clinical,	and	laboratory	data	at	diagnosis	of	AAV	were	
described in Table 1. The most common clinical manifestation at 
diagnosis	 was	 renal	 involvement	 (58.2%),	 followed	 by	 pulmonary	
involvement	 (56.0%).	The	median	BVAS	and	FFS	 (2009)	at	diagno‐
sis	were	12.0	 (11.0)	and	1.0	 (1.0),	 respectively.	The	median	values	
of	 laboratory	 results	were	shown	 in	Table	1.	During	 the	 follow‐up	
of	 the	median	duration	of	39.5	 (72.0)	months,	36	patients	 (19.8%)	
had	diabetes	mellitus	and	76	patients	(41.8%)	had	hypertension.	The	
most	frequently	administered	 immunosuppressive	drug	was	gluco‐
corticoid	 (86.8%),	 followed	by	cyclophosphamide	 (41.8%)	and	aza‐
thioprine	(53.3%).	Fifteen	patients	(8.2%)	died	of	all	etiologies	during	
follow‐up	(Table	1).
3.2 | Comparison of laboratory variables at 




two groups. Because clinical manifestations at diagnosis were based 
on	all	 items	of	BVAS,	as	was	expected,	patients	with	BVAS	at	diag‐
nosis	≥16	exhibited	the	higher	frequencies	of	renal,	pulmonary,	gen‐








3.3 | Optimal cutoffs of laboratory variables for 
severe AAV at diagnosis
We obtained the optimal cutoffs of laboratory variables at diag‐
nosis	 for	 severe	 AAV,	 which	 were	 significant	 in	 the	 comparative	
analysis	 between	 patients	with	 and	without	 severe	AAV.	 The	 op‐
timal	cutoffs	of	variables	are	as	below:	neutrophil	count	≥	7570.0/
mm3;	 lymphocyte	 count	 ≤	 1430.0/mm3;	 hemoglobin	 ≤	 10.8	 g/dL;	
platelet	count	≥	352	500.0/mm3;	creatinine	≥	0.9	mg/dL;	serum	al‐
bumin	≤	3.5	g/dL;	ESR	≥	83.5	mm/h;	and	CRP	≥	20.0	mg/L	 (Table	
S1).	 Although	 platelet	 count	 exhibited	 no	 statistical	 significance	
(area	0.568,	95%	confidence	interval	(CI)	0.475,	0.661),	we	included	
platelet	count	≥	352	500.0/mm3	in	the	logistic	regression	analyses,	
because it significantly differed between patients with and without 
severe	AAV	in	the	comparison	analysis.
3.4 | Univariable and multivariable logistic 
regression analyses for severe AAV at diagnosis
Since	there	were	no	significant	differences	 in	age	at	diagnosis	and	
gender	 between	 the	 two	 groups,	 we	 did	 not	 include	 them	 in	 the	
univariable and multivariable logistic regression analyses. In the 
univariable logistic regression analysis of laboratory variables at 
diagnosis	for	severe	AAV,	all	 laboratory	variables	with	significance	
in the comparative analysis exhibited significant ORs: neutrophil 
count	 ≥	 7570.0/mm3	 (OR	 2.499);	 lymphocyte	 count	 ≤	 1430.0/
mm3	 (OR	 2.664);	 hemoglobin	 ≤	 10.8	 g/dL	 (OR	 4.348);	 platelet	
count	 ≥	 352	 500.0/mm3	 (OR	 2.325);	 creatinine	 ≥	 0.9	 mg/dL	 (OR	
3.536);	serum	albumin	≤	3.5	g/dL	(OR	2.770);	ESR	≥	83.5	mm/h	(OR	
3.051);	and	CRP	≥	20.0	mg/L	(OR	2.770;	Table	3).	In	the	multivariable	










We assigned a weight of a number close to an integer to each 
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or	no	=	0).	For	instance,	if	a	patient	had	lymphocyte	≤	1430.0/mm3,	
hemoglobin	 ≤	 10.8	 g/dL,	 and	 creatinine	 ≥	 0.9	mg/dL,	 that	 patient	
would	have	MVIA	of	2.1	(0.6	×	1	+	0.7	×	1	+	0.8	×	1).














3.7 | Cumulative patient survival rate
We	investigated	the	cumulative	patient	survival	rate	during	follow‐
up	 between	 patients	 with	 and	 without	 MVIA	 at	 diagnosis	 ≥1.35.	











































































TA B L E  1   (Continued)


























identified	 more	 frequently	 in	 patients	 with	 MVIA	 at	 diagno‐








mm3	 and	 hemoglobin	 ≤	 10.8	 g/dL	 also	 tended	 to	 be	 associated	




stable	 and	 reliable.	 For	 these	 reasons,	 MVIA	 showed	 the	 high‐





the present study received the proper induction and maintenance 
therapies	based	on	the	cross‐sectional	activity.2,14 When we divided 
patients	with	AAV	 into	the	two	groups	based	on	MVIA	at	diagno‐
sis	 ≥1.35,	 79	 patients	 belonged	 to	 the	 group	 of	MVIA	 at	 diagno‐
sis	 ≥1.35.	We	 compared	 the	 use	 of	 cyclophosphamide,	 rituximab,	









agnosis < 16 
(N = 119) P value
Demographic data at diagnosis
Age	(year	old) 62.0	(23.0) 56.0	(21.0) .057
Male	gender	(N,	[%]) 16	(25.4) 39	(32.8) .303
Clinical	manifestations	at	diagnosis	(N,	[%])
Renal 55	(87.3) 51	(42.9) <.001
Pulmonary 42	(66.7) 60	(50.4) .036
General 39	(61.9) 41	(34.5) <.001
Ear	Nose	Throat 21	(33.3) 47	(39.5) .414
Nervous	system 23	(36.5) 33	(27.7) .222
Cardiovascular 28	(44.4) 19	(16.0) <.001




Gastrointestinal 7	(11.1) 3	(2.5) .016
Laboratory	results	at	diagnosis













Hemoglobin	(g/dL) 9.9	(3.2) 12.3	(3.1) <.001
Platelet	(×1000/mm3) 337.0	(256.5) 301.0	(143.5) .032
Prothrombin	time	(INR) 1.0	(0.2) 1.0	(0.2) .310
Fasting	glucose	(mg/dL) 100.0	(33.0) 101.0	(34.0) .896
Blood urea nitrogen 
(mg/dL)
24.6	(23.8) 15.2	(11.8) .002
Creatinine	(mg/dL) 1.4	(2.1) 1.2	(0.7) .010
Total	protein	(g/dL) 6.4	(1.2) 6.8	(1.1) .910










Total	bilirubin	(mg/dL) 0.4	(0.3) 0.5	(0.2) .361
ESR	(mm/h) 69.0	(88.0) 49.0	(59.0) .005








cluded only creatinine in the analysis. 
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and	azathioprine	between	patients	with	MVIA	at	diagnosis	≥1.35	and	
those without. Cyclophosphamide was administered to patients with 
MVIA	at	diagnosis	≥1.35	more	frequently	than	those	without	(44.7%	
vs	 29.1%,	 P	 <	 .001).	 Rituximab	 was	 evenly	 administered	 to	 both	






have	been	applied	 to	patients	with	 the	high	 severity	of	AAV.	This	
further	highlights	our	study	 that	MVIA	at	diagnosis	could	be	used	






thermore,	 if	 we	 develop	 an	 automatic	 calculator	 of	MVIA,	 severe	
AAV	based	on	BVAS	may	be	rapidly	and	promptly	assessed.
TA B L E  3  Logistic	regression	analyses	for	severe	AAV	at	diagnosis
Variables at diagnosis
Univariable Multivariable
OR 95% CI P value B OR 95% CI P value
Neutrophil	≥7570.0/mm3 2.499 1.334,	4.681 .004 0.332 1.394 0.627,	3.099 .416
Lymphocyte	≤	1430.0/mm3 2.664 1.418,	5.007 .002 0.619 1.856 0.906,	3.804 .091
Hemoglobin	≤	10.8	g/dL 4.348 2.272,	8.320 .001 0.735 2.085 0.917,	4.737 .079
Platelet	≥	352	500.0/mmy3 2.325 1.236,	4.374 .009 0.448 1.566 0.624,	3.931 .340
Creatinine	≥	0.9	mg/dL 3.536 1.805,	6.926 <.001 0.817 2.264 1.107,	5.040 .045
Serum	albumin	≤	3.5	g/dL 2.770 1.475,	5.202 .002 0035 1.036 0.457,	2.348 .933
ESR	≥	83.5	mm/h 3.051 1.578,	5.898 .001 0.507 1.660 0.682,	4.045 .264
CRP	≥	20.0	mg/L 2.770 1.475,	5.202 .002 0.023 1.023 0.427,	2.452 .960
Abbreviations:	AAV,	antineutrophil	cytoplasmic	antibody	(ANCA)‐associated	vasculitis;	ANCA,	antineutrophil	cytoplasmic	antibody;	CRP,	C‐reactive	
protein;	ESR,	erythrocyte	sedimentation	rate.










antineutrophil cytoplasm antibody 
(ANCA)‐associated	vasculitis;	MVIA,	a	
multivariable	index	for	AAV





count may also be affected by general health and stress or various 
autoimmune diseases and we previously proved the lower number 
of	 lymphocyte	 in	 severe	 AAV	 compared	 with	 non‐severe	 AAV.15 




We	 found	 that	MVIA	 at	 diagnosis	 ≥1.35	 was	 significantly	 as‐
sociated	 with	 all‐cause	 mortality.	 Although	 the	 poor	 prognosis	




AAV	 variants:	 BVAS	was	 associated	with	 relapse	 of	MPA	 and	 re‐
fractory	disease	of	GPA,	but	not	with	the	prognosis	of	EGPA.	In	this	
study,	BVAS	at	diagnosis	≥16	could	not	predict	all‐cause	mortality	
in	 patients	with	AAV.	Whereas,	 patients	with	 FFS	 (2009)	 at	 diag‐
nosis	 ≥2	 exhibited	 the	 higher	 all‐cause	mortality	 rate	 than	 those	



















mm3;	 lymphocyte	 count	 ≤	 1475.0/mm3;	 hemoglobin	 ≤	 10.8	 g/
dL;	 creatinine	 ≥	 1.16	 mg/dL;	 serum	 albumin	 ≤	 3.65	 g/dL;	 and	
CRP	 ≥39.35	 mg/L	 (Table	 S2).	 In	 the	 univariable	 logistic	 regres‐
sion	analysis,	significant	ORs	for	FFS	at	diagnosis	≥2	were	found	
in all variables with the significant cutoffs. In the multivariable 
logistic	 regression	 analysis,	 neutrophil	 ≥	 7570.0/mm3,	 hemoglo‐
bin	≤	10.8	g/dL,	and	creatinine	≥	1.16	mg/dL	were	significantly	as‐
sociated	with	FFS	at	diagnosis	≥2	(Table	S3).	We	assigned	a	weight	




addition,	we	obtained	 the	 optimal	 cutoff	 of	MVIA	 for	 FFS	 at	 di‐
agnosis	≥2	as	1.75	 (sensitivity	0.667	and	 specificity	0.689)	using	
the	AUROC	 curve	 (area	 0.850;	 Figure	 S2).	We	 found	 that	MVIA	






Our study has several limitations. This study is based on study 
population that was not large enough to represent the clinical data 
of	 all‐Korean	 patients	 with	 AAV.	 Also,	 due	 to	 the	 retrospective	
study	design,	the	usefulness	of	MVIA	was	not	explored	for	assess‐
ing	the	serially	changing	the	cross‐sectional	activity	and	severity	
of	 AAV	 under	 the	 administration	 of	 immunosuppressive	 drugs.	
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